Literature DB >> 6801283

Oral correction of essential fatty acid deficiency in cystic fibrosis.

C Landon, J A Kerner, R Castillo, L Adams, R Whalen, N J Lewiston.   

Abstract

A combination of pancreatic insufficiency and inadequate caloric intake may produce essential fatty acids (EFA) deficiency in patients with cystic fibrosis. Seventy-five percent of the adolescents and young adults with poor weight gain in our clinic were EFA-deficient by total plasma linoleic acid criteria. Twenty of these patients were placed on an oral hyperalimentation regimen containing 230% of calories required for basal energy expenditure, 40% as fat. Forty percent of these (8/20) achieved normal EFA levels on this diet. Eight of the nonresponding patients were given an additional 5% of their caloric intake as linoleic acid monoglyceride. All who maintained caloric intake achieved normal EFA levels. Normalization of EFA levels was associated with a number of clinical benefits including increase in weight and activity and, in five teenage girls, regulation of menses. The 16 control patients who received standard pancrelipase therapy and nutritional supplements remained fatty acid deficient. We conclude that oral hyperalimentation can restore EFA levels in cystic fibrosis patients if adequate calories are available to provide energy needs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6801283     DOI: 10.1177/0148607181005006501

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  10 in total

Review 1.  Cystic fibrosis--a gastroenterological cornucopia.

Authors:  P L Zentler-Munro
Journal:  Gut       Date:  1987-11       Impact factor: 23.059

2.  What is the association of essential fatty acid status with cystic fibrosis?

Authors:  V S Hubbard
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

3.  Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis.

Authors:  H Yu; S Z Nasr; V Deretic
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

4.  Altered de novo lipogenesis contributes to low adipose stores in cystic fibrosis mice.

Authors:  Ilya Bederman; Aura Perez; Leigh Henderson; Joshua A Freedman; James Poleman; Dana Guentert; Nicholas Ruhrkraut; Mitchell L Drumm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-06-07       Impact factor: 4.052

5.  Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis.

Authors:  Asim Maqbool; Joan I Schall; J Felipe Garcia-Espana; Babette S Zemel; Birgitta Strandvik; Virginia A Stallings
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-11       Impact factor: 2.839

6.  Absorption of safflower oil and structured lipid preparations in patients with cystic fibrosis.

Authors:  V S Hubbard; M C McKenna
Journal:  Lipids       Date:  1987-06       Impact factor: 1.880

7.  Mechanisms of lipid malabsorption in Cystic Fibrosis: the impact of essential fatty acids deficiency.

Authors:  N Peretti; V Marcil; E Drouin; E Levy
Journal:  Nutr Metab (Lond)       Date:  2005-05-03       Impact factor: 4.169

8.  Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms.

Authors:  Bernard Cuenoud; Isabelle Rochat; Maria Laura Gosoniu; Lenaick Dupuis; Evan Berk; Anke Jaudszus; Jochen G Mainz; Gaudenz Hafen; Maurice Beaumont; Cristina Cruz-Hernandez
Journal:  Nutrients       Date:  2020-04-07       Impact factor: 5.717

Review 9.  Auxological and Endocrinological Features in Children and Adolescents with Cystic Fibrosis.

Authors:  Vittorio Ferrari; Vito Terlizzi; Stefano Stagi
Journal:  J Clin Med       Date:  2022-07-13       Impact factor: 4.964

10.  The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients.

Authors:  Caroline Morin; André M Cantin; Félix-Antoine Vézina; Samuel Fortin
Journal:  Mar Drugs       Date:  2018-05-26       Impact factor: 5.118

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.